SION: Sionna Pharma Price to Sales

Corporate company logo of Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics Inc (SION) is recruiting top biochemists to develop genetics patents. This chart illustrates the revenue valuation based on GURU.Markets data, where the current value stands at . The company is developing treatments for cystic fibrosis, aiming to generate profit from the restoration of protein functions; however, the lack of finished products and the costs of testing are limiting the business's scalability.

SION: Sionna Therapeutics Inc P/S Multiple 07/04/2022 - 11/16/2026

Analytical breakdowns for Sionna Therapeutics, Inc. (SION)

Summary company analytics:SION Sionna Pharma
Flagship merchandise of Sionna Therapeutics

For the biotech sector company Sionna Therapeutics Inc (SION), which focuses on CFTR protein restoration for cystic fibrosis, valuation is based on future market prospects. By analyzing the price-to-sales multiple, an investor compares the asset's current market price with actual sales volume to determine the premium paid for the therapy's potential and minimize the risk of a deep correction driven by inflated expectations.

Who Sionna Therapeutics Inc competes with

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Beam Therapeutics Inc.|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Revenue Ratio|10x Genomics Inc - Market Cap to Revenue|NTLA (Intellia Therapeutics, Inc.) - Price-to-Sales Ratio|Stoke Corp - P/S Multiple|BLFS (BioLife) - Market Cap to Revenue Ratio|wavelifesciences.com (WVE) - Price-to-Revenue Ratio|MAZE - Price-to-Revenue Coefficient|PRME (Prime Medicine Inc) - P/S Multiple|Taysha Gene Therapies, Inc. - Price-to-Sales Ratio|P/S Multiple QURE|MGTX: Price-to-Sales Ratio|Price-to-Revenue Ratio REGENXBIO RGNX|SLDB: Market Cap to Revenue Ratio|OCGN: Market Cap to Revenue|PACB - P/S Multiple|BNTC (Benitec Corp) - Market Cap to Revenue|Price-to-Revenue Multiple Design Corp DSGN|Price-to-Revenue Ratio Rocket Pharmaceuticals|P/S Multiple 4D Molecular Therapeutics, Inc.|Price-to-Revenue Ratio Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple EDIT (Editas Medicine, Inc.)|P/S Multiple Silence Therapeutics Corp SLN|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis Inc CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio